<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2018-07-09">2018 July 09.</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">S</forename><surname>Kayser</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine V</orgName>
								<orgName type="institution">University Hospital of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Internal Medicine V</orgName>
								<orgName type="department" key="dep2">Clinical Cooperation Unit Molecular Hematology/Oncology</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">University of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Krzykalla</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Division of Biostatistics</orgName>
								<orgName type="institution">German Cancer Research Center</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Elliott</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Division of Hematology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>Minnesota</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Norsworthy</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution" key="instit1">Sidney Kimmel Comprehensive Cancer Center</orgName>
								<orgName type="institution" key="instit2">Johns Hopkins University</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>Maryland</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Gonzales</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">Leukemia Service</orgName>
								<orgName type="institution" key="instit1">Memorial Sloan Kettering Cancer Center</orgName>
								<orgName type="institution" key="instit2">Weill Cornell Medical College</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Hills</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">Cardiff University School of Medicine</orgName>
								<address>
									<settlement>Cardiff</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Baer</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">University of Maryland Greenebaum Comprehensive Cancer Center</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">University of Maryland School of Medicine</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Z</forename><surname>Ráčil</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Internal Medicine, Hematology and Oncology</orgName>
								<orgName type="institution">Masaryk University and University Hospital Brno</orgName>
								<address>
									<settlement>Brno</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Mayer</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Internal Medicine, Hematology and Oncology</orgName>
								<orgName type="institution">Masaryk University and University Hospital Brno</orgName>
								<address>
									<settlement>Brno</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Novak</surname></persName>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Žák</surname></persName>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Faculty of Medicine</orgName>
								<orgName type="department" key="dep2">4th Department of Internal Medicine-Hematology</orgName>
								<orgName type="institution">Charles University and University Hospital Hradec Králové</orgName>
								<address>
									<settlement>Hradec Králové</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Szotkowski</surname></persName>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Faculty of Medicine and Dentistry</orgName>
								<orgName type="department" key="dep2">Department of Hemato-Oncology</orgName>
								<orgName type="institution">Palacky University Olomouc and University Hospital Olomouc</orgName>
								<address>
									<settlement>Olomouc</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Grimwade</surname></persName>
							<affiliation key="aff15">
								<orgName type="department" key="dep1">Faculty of Life Sciences and Medicine</orgName>
								<orgName type="department" key="dep2">Department of Medical &amp; Molecular Genetics</orgName>
								<orgName type="institution">King&apos;s College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Russell</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Haematology</orgName>
								<orgName type="institution">Nottingham University Hospitals NHS Trust</orgName>
								<address>
									<settlement>Nottingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Walter</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Division of Clinical Research</orgName>
								<orgName type="institution">Fred Hutchinson Cancer Research Center</orgName>
								<address>
									<settlement>Seattle</settlement>
									<region>WA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="department">Division of Hematology/Department of Medicine</orgName>
								<orgName type="institution">University of Washington</orgName>
								<address>
									<settlement>Seattle</settlement>
									<region>WA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="department">Department of Epidemiology</orgName>
								<orgName type="institution">University of Washington</orgName>
								<address>
									<settlement>Seattle</settlement>
									<region>WA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Estey</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Division of Clinical Research</orgName>
								<orgName type="institution">Fred Hutchinson Cancer Research Center</orgName>
								<address>
									<settlement>Seattle</settlement>
									<region>WA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="department">Division of Hematology/Department of Medicine</orgName>
								<orgName type="institution">University of Washington</orgName>
								<address>
									<settlement>Seattle</settlement>
									<region>WA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Westermann</surname></persName>
							<affiliation key="aff20">
								<orgName type="department">Department of Hematology, Oncology and Tumor Immunology</orgName>
								<orgName type="institution">Charité-University Medical Center</orgName>
								<address>
									<addrLine>Campus Virchow Clinic</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Görner</surname></persName>
							<affiliation key="aff21">
								<orgName type="institution" key="instit1">Klinik für Hämatologie</orgName>
								<orgName type="institution" key="instit2">Onkologie und Palliativmedizin</orgName>
								<address>
									<addrLine>Klinikum Bielefeld Mitte</addrLine>
									<settlement>Bielefeld</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Benner</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Division of Biostatistics</orgName>
								<orgName type="institution">German Cancer Research Center</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Krämer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine V</orgName>
								<orgName type="institution">University Hospital of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Internal Medicine V</orgName>
								<orgName type="department" key="dep2">Clinical Cooperation Unit Molecular Hematology/Oncology</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">University of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Smith</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution" key="instit1">Sidney Kimmel Comprehensive Cancer Center</orgName>
								<orgName type="institution" key="instit2">Johns Hopkins University</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>Maryland</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Burnett</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Haematology</orgName>
								<orgName type="institution">Nottingham University Hospitals NHS Trust</orgName>
								<address>
									<settlement>Nottingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Thiede</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="institution">University Hospital Carl-Gustav-Carus</orgName>
								<address>
									<settlement>Dresden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Röllig</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="institution">University Hospital Carl-Gustav-Carus</orgName>
								<address>
									<settlement>Dresden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Ho</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine V</orgName>
								<orgName type="institution">University Hospital of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Ehninger</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="institution">University Hospital Carl-Gustav-Carus</orgName>
								<address>
									<settlement>Dresden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Schlenk</surname></persName>
							<affiliation key="aff23">
								<orgName type="department">National Center for Tumor Diseases</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Levis</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution" key="instit1">Sidney Kimmel Comprehensive Cancer Center</orgName>
								<orgName type="institution" key="instit2">Johns Hopkins University</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>Maryland</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">Leukemia Service</orgName>
								<orgName type="institution" key="instit1">Memorial Sloan Kettering Cancer Center</orgName>
								<orgName type="institution" key="instit2">Weill Cornell Medical College</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">U</forename><surname>Platzbecker</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="institution">University Hospital Carl-Gustav-Carus</orgName>
								<address>
									<settlement>Dresden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="department">Department of Internal Medicine V</orgName>
								<orgName type="institution">University Hospital of Heidelberg</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 410</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Faculty of Medicine</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine and Haematology</orgName>
								<orgName type="department" key="dep3">Faculty Hospital Kralovske Vinohrady</orgName>
								<orgName type="institution">Charles University</orgName>
								<address>
									<addrLine>11 3rd</addrLine>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2018-07-09">2018 July 09.</date>
						</imprint>
					</monogr>
					<idno type="MD5">FB579BC11AB9D4FAE915D48CEB82E7A8</idno>
					<idno type="DOI">10.1038/leu.2017.92</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:43+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Therapy-related acute promyelocytic leukemia (t-APL) is relatively rare, with limited data on outcome after treatment with arsenic trioxide (ATO) compared to standard intensive chemotherapy (CTX).</s><s>We evaluated 103 adult t-APL patients undergoing treatment with all-trans retinoic acid (ATRA) alone (n = 7) or in combination with ATO (n = 24), CTX (n = 53), or both (n = 19).</s><s>Complete remissions were achieved after induction therapy in 57% with ATRA, 100% with ATO/ ATRA, 78% with CTX/ATRA, and 95% with CTX/ATO/ATRA.</s><s>Early death rates were 43% for ATRA, 0% for ATO/ATRA, 12% for CTX/ATRA and 5% for CTX/ATO/ATRA.</s><s>Three patients relapsed, two developed therapy-related acute myeloid leukemia and 13 died in remission including seven patients with recurrence of the prior malignancy.</s><s>Median follow-up for survival was 3.7 years.</s><s>None of the patients treated with ATRA alone survived beyond one year.</s><s>Event-free survival was significantly higher after ATO-based therapy (95%, 95% CI, 82-99%) as compared to CTX/ATRA (78%, 95% CI, 64-87%; P= 0.042), if deaths due to recurrence of the prior malignancy were censored.</s><s>The estimated 2-year overall survival in intensively treated patients was 88% (95% CI, 80-93%) without difference according to treatment (P= 0.47</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>2]<ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref> In recent publications, 15-21% of all APL cases were considered therapy-related, <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b5">6</ref> as compared to 8% reported in 2002. <ref type="bibr" target="#b6">7</ref></s><s><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref> Nevertheless, the term 'therapy-related' leukemia is merely descriptive and based upon a patient's history of exposure to chemo and/or radiotherapy.</s><s>0]<ref type="bibr" target="#b10">[11]</ref> However, recent work has identified specific hot spots in the breakpoint region of PML and RARA genes as preferential sites of topo-II-mediated DNA damage, underscoring their causative role in the etiology of t-APL. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b12">13</ref></s><s>nce its clinical introduction in 1986, treatment with all-trans retinoic acid (ATRA) has significantly changed therapeutic success in APL. <ref type="bibr" target="#b13">14</ref> ATRA causes differentiation of abnormal promyelocytes to mature granulocytes. <ref type="bibr" target="#b14">15</ref></s><s><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref> These findings led to the concurrent use of ATRA with chemotherapy (either an anthracycline plus cytarabine or an anthracycline alone) as the standard of care for induction in newly diagnosed APL. <ref type="bibr" target="#b20">21</ref></s><s>More recently, the combination of arsenic trioxide (ATO) with ATRA have been shown to be a very effective chemotherapy-free treatment strategy in de novo APL, with a CR rate of 96%. <ref type="bibr" target="#b21">22</ref></s><s>In addition, published data of a large multicenter phase 3 randomized trial on the direct comparison of ATO/ATRA vs ATRA in combination with idarubicin (AIDA) or mitoxantrone in the Gruppo Italiano Malattie EM atologiche dell'Adulto (GIMEMA)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) scheme showed very promising results in favor of ATO/ATRA, with a 2-year event-free survival (EFS) of 97 vs 86% (P= 0.02). <ref type="bibr" target="#b22">23</ref></s><s>Within this trial, early mortality as well as hematological toxicities were significantly lower in patients treated with ATO/ ATRA as compared to AIDA. <ref type="bibr" target="#b22">23</ref></s><s>Additional support comes from another publication out of the Medical Research Council with a 4-year EFS of 91% after ATO/ATRA as compared to 70% after chemotherapy (CTX)/ATRA (P= 0.002). <ref type="bibr" target="#b23">24</ref></s><s>Therefore, this non-chemotherapeutic approach seems to be of great benefit.</s></p><p><s>Prior publications have suggested that characteristics and outcomes of t-APL when treated appropriately were similar to those of de novo APL patients, <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b6">7</ref> but this has not been systematically evaluated in a large cohort of patients.</s><s>Most importantly, the clinical impact of ATO/ATRA on outcome in patients with t-APL is unknown, and this was the rationale for this multi-institutional analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PATIENTS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and treatment</head><p><s>Information on 103 patients with t-APL occurring after chemotherapy and/or radiation for a previous neoplasm or non-malignant disorder between 1991 and 2015 was collected from 11 study groups/institutions in the US and Europe.</s><s>Patients with APL that occurred after a neoplasm treated by surgery or hormonal therapy only were excluded.</s><s>To obtain patient information, detailed case report forms (including type of primary malignancy or nonmalignant disorder and related treatment, occurrence of t-APL, its baseline characteristics, t-APL treatment, adverse events during t-APL treatment, response as well as follow-up data) were sent to all participating centers.</s></p><p><s>Diagnosis of APL was based on French-American-British Cooperative Group criteria, <ref type="bibr" target="#b24">25</ref> and, after 2003, on revised International Working Group criteria. <ref type="bibr" target="#b25">26</ref></s><s>Chromosome banding was performed using standard techniques, and karyotypes were described according to the International System for Human Cytogenetic Nomenclature. <ref type="bibr" target="#b26">27</ref></s><s>The diagnosis was confirmed by either reverse-transcriptase polymerase chain reaction or fluorescence in situ hybridization detection of the PML-RARA fusion gene in bone marrow by standard methods.</s><s>FLT3 mutation screening for internal tandem duplications (ITD) and point mutations within the tyrosine kinase domain (TKD) was carried out as previously described. <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29</ref></s><s>Data collection and analysis were approved by the Institutional Review Boards.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment</head><p><s>Fifty-three (51.5%) t-APL patients were treated with ATRA and an anthracycline (daunorubicin or idarubicin) as induction and different chemotherapies in combination with ATRA as consolidation therapy according to treatment protocols active in various countries.</s><s>These protocols included the AIDA 2000 protocol of the Italian GIMEMA study group, <ref type="bibr" target="#b29">30</ref> the PETHEMA LPA99 and LPA2005 protocols <ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b31">32</ref> and the United Kingdom AML15 <ref type="bibr" target="#b32">33</ref> and AML17 <ref type="bibr" target="#b23">24</ref> protocols.</s><s>Twenty-four (23.3%) patients were treated with ATO/ATRA (according to Lo-Coco et al. <ref type="bibr" target="#b22">23</ref> (n = 21) or Burnett et al. <ref type="bibr" target="#b23">24</ref> (n = 3)) and 19 (18.4%) patients received ATO/ATRA in combination with chemotherapy (according to Gore et al. <ref type="bibr" target="#b33">34</ref> or comparable schemes).</s><s>Seven (6.8%) patients with advanced age and/or poor performance status received monotherapy with ATRA only.</s></p><p><s>Response was assessed according to Cheson et al. <ref type="bibr" target="#b25">26</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>Survival endpoints including overall survival (OS), EFS, relapse-free survival (RFS), cumulative incidence of relapse and cumulative incidence of death in CR were defined as recommended. <ref type="bibr" target="#b25">26</ref></s><s>In addition to the international criteria we included death due to primary malignancy as an event for EFS and RFS.</s></p><p><s>Comparisons of patient characteristics were performed with the Kruskal-Wallis rank sum test for continuous variables and Fisher's exact test for categorical variables, respectively.</s><s>A multivariable linear regression model was used to identify factors that influence the duration of the latency period from prior malignancy/non-malignant disorder to the diagnosis of t-APL measured on log-scale, including the covariates age at diagnosis of primary malignancy/non-malignant disorder, gender, prior chemotherapy and prior radiation.</s><s>The chemotherapeutic subcategories 'prior treatment with intercalating agents' or 'topo-II inhibitors' were not included due to low numbers.</s><s>The median follow-up time was computed using the reverse Kaplan-Meier estimate. <ref type="bibr" target="#b34">35</ref></s><s>The Kaplan-Meier method was used to estimate the distribution of RFS, EFS and OS. <ref type="bibr" target="#b35">36</ref></s><s>onfidence interval (CI) estimation for survival curves was based on the cumulative hazard function using Greenwood's formula for variance estimation.</s><s>Log-rank tests were employed to compare survival curves between groups.</s><s>A Cox proportional hazards regression model was used to identify prognostic variables for EFS, RFS and OS. <ref type="bibr" target="#b36">37</ref></s><s>The following variables were included in the Cox models: age at diagnosis of t-APL, gender, t-APL treatment (ATO/ ATRA vs CTX/ATO/ATRA vs CTX/ATRA), prior chemotherapy, prior radiotherapy, white blood cells (WBC; dichotomized according to high vs intermediate/low risk) and duration of the latency period between diagnosis of primary malignancy/non-malignant disorder and the occurrence of t-APL.</s><s>All statistical analyses were performed with the statistical software environment R, version 3.3.1,</s><s>using the R packages prodlim, version 1.5.7 and survival, version 2.39-5. <ref type="bibr" target="#b37">38</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>In total, 103 adult t-APL patients, diagnosed between 1991 and 2015 from 11 study centers/ institutions in the US and Europe, were included.</s><s>Median age was 59 years (range, 18-80 years).</s><s>Most of the patients had French-American-British M3 (n = 94), whereas the M3 variant was very rare (n = 7); information on sub-variant category was missing in n = 2 patients.</s></p><p><s>Risk categorization based on WBC at diagnosis was available in 99 (96%) of the 103 patients and was low/intermediate-risk (WBC &lt; 10.0 G/l) in 79 (80%) and high-risk (WBC ≥ 10.0 G/l) in 20 (20%) patients.</s></p><p><s>Information on cytogenetics was available in 84 (82%) patients.</s><s>In 62 (74%) of the 84 patients, the balanced t(15;17) translocation was the sole abnormality, whereas in 22 (26%) patients, the translocation was accompanied by additional cytogenetic abnormalities, most frequently various deletions (n = 8) including del(7q) (n = 2) and del(5q) (n = 1), followed by variant translocations (n = 7) as well as trisomy 8 (n = 5) or trisomy 8 in combination with other abnormalities (n = 1; del(9)(q21) and monosomy X).</s><s>One patient had an additional trisomy 21.</s></p><p><s>Regarding FLT3-ITD and TKD mutations, information was available in 51 (50%) of the 103 patients.</s><s>Of those, 17 (33%) patients had FLT3-ITD, three (6%) had a FLT3-TKD mutation and three (6%) additional patients displayed both FLT3-ITD and TKD mutation.</s><s>Notably, FLT3-ITD mutated patients had significantly higher WBC at diagnosis as compared to FLT3 wild type patients (P= 0.03).</s></p><p><s>Congruently, cytogenetic as well as molecular data on FLT3 were available in 44 patients.</s><s>Interestingly, only 4 of 15 (27%) patients with additional cytogenetic abnormalities were FLT3 mutated (two with an ITD, one with a TKD and one additional patient with both mutations).</s><s>In contrast, 18 of 29 (62%) patients without additional cytogenetic abnormalities displayed FLT3 mutations (P= 0.05).</s></p><p><s>Information on the PML-RARA transcript isoform (breakpoint cluster region, BCR) was available in 52 patients for BCR3 (short isoform) and 45 patients for BCR1 (long isoform).</s><s>Of those, 58% (n = 30/52) displayed the BCR3 isoform, whereas 33% (n = 15/45) were BCR1-positive.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary diseases, previous therapy and latency period to the occurrence of t-APL</head><p><s>The median latency period between diagnosis of primary malignancy/non-malignant disease and the occurrence of t-APL was 3.5 years (range, 0.4-26.2</s><s>years).</s><s>Eighty-seven (84%) patients with t-APL had a previous solid cancer (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Among these, breast cancer was the most common neoplasm (n = 38; 37%), followed by prostate (n = 14; 14%), head and neck (n = 9; 9%) and gastrointestinal (n = 9; 9%) cancers.</s><s>Five (5%) patients (one male/four females) had two solid cancers prior to the occurrence of t-APL (colon and prostate; breast and lung; cervix and breast; breast and uterus; ovarian and breast; n = 1 each).</s><s>Eight (8%) patients had a primary hematologic malignancy: five with non-Hodgkin lymphoma and three with Hodgkin lymphoma.</s><s>In addition, eight (8%) patients had undergone cytotoxic therapy for the treatment of an autoimmune disease (four with multiple sclerosis treated with mitoxantrone, four with rheumatologic disorders treated with methotrexate; Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>Treatment prior to the occurrence of t-APL included chemotherapy only in 28 (27%) patients, radiation in 40 (39%), and both chemotherapy and radiation in 35 (34%), respectively.</s><s>Detailed information on type of chemotherapeutic agents was available in 53 (84%) of the 63 patients, who had been treated with chemotherapy with or without radiation (Table <ref type="table">2</ref>).</s><s>Of those, only 16 (30%) patients received single-agent chemotherapy.</s><s>For further analysis, we classified chemotherapeutic agents according to mechanism of action. <ref type="bibr" target="#b7">8</ref></s><s>In univariable analysis, prior treatment with neither intercalating agents (P= 0.81) nor topo-II inhibitors (P= 0.46) was associated with the length of the latency period between diagnosis of primary malignancy and the occurrence of t-APL.</s><s>In multivariable analysis, only younger age at diagnosis of primary malignancy (P= 0.07) and prior radiation (P= 0.06) were in trend associated with a shorter latency period.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comparison of baseline characteristics</head><p><s>Women were more frequently affected than men (binominal test, P &lt; 0.001), possibly due to the high frequency of t-APL after treatment of breast cancer.</s><s>In a direct comparison of the four treatment groups (CTX/ATRA; ATO/ATRA; CTX/ATO/ATRA; ATRA), the baseline characteristics were comparable except for age (P= 0.002) and platelet counts (P= 0.009), in that patients treated with ATRA alone were older and had lower platelet counts (Table <ref type="table" target="#tab_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Response to induction therapy</head><p><s>Response data were available in 100/103 (97%) patients (missing: CTX/ATRA, n = 2; ATO/ ATRA, n = 1).</s><s>Early death (ED) rates were 43% for ATRA (n = 3), 0% for ATO/ATRA, 12% for CTX/ATRA (n = 6) and 5% for CTX/ATO/ATRA (n = 1).</s><s>Of those, n = 5 EDs occurred between 1991-2009 (after n = 52/103 (50%) patients had been included) and additionally n = 5 EDs between 2010-2015.</s></p><p><s>CRs were achieved after induction therapy in 57% of the patients treated with ATRA (n = 4), 100% with ATO/ATRA (n = 23), 78% with CTX/ATRA (n = 40/51) and 95% with CTX/ATO/ATRA (n = 18).</s><s>Five of the CTX/ATRA patients achieved a partial remission after induction therapy.</s><s>All of them went on to consolidation therapy and achieved CR thereafter (Table <ref type="table" target="#tab_3">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survival analysis</head><p><s>Median follow-up for survival was 3.7 years.</s><s>The estimated 2-year EFS, RFS and OS rates in intensively treated patients (excluding the patients treated with ATRA only) were 84% (95% CI, 75-90%), 84% (95% CI, 75-91%) and 88% (95% CI, 80-93%), respectively and were not significantly different according to treatment groups (P= 0.23, P= 0.24 and P= 0.47, respectively).</s></p><p><s>Stratified by treatment, estimated 2-year EFS rates were 78% (95% CI, 64-87%) in patients treated with CTX/ATRA, 89% (95% CI, 64-97%) in the ATO/ATRA group and 95% (95% CI, 68-99%) in the CTX/ATO/ATRA group (Figure <ref type="figure" target="#fig_1">1a</ref>).</s><s>The estimated 2-year RFS rates were 78% (95% CI, 64-87%) in the CTX/ATRA group, 90% (95% CI, 68-98%) in the ATO/ ATRA and 95% (95% CI, 68-99%) in the CTX/ATO/ATRA groups.</s><s>The estimated 2-year OS rates for patients receiving CTX/ATRA were 84% (95% CI, 71-92%), 89% (95% CI, 64-97%) for ATO/ATRA and 95% (95% CI, 68-99%) for CTX/ATO/ATRA (Figure <ref type="figure" target="#fig_1">1b</ref>).</s><s>None of the patients treated with ATRA alone survived beyond 1 year.</s><s>Cumulative incidence of relapse including relapse and occurrence of secondary AML as events in intensively treated patients showed a strong trend towards a higher cumulative incidence of relapse after treatment with CTX/ATRA as compared to ATO-based regimens (including ATO/ATRA and CTX/ATO/ATRA; P= 0.07), whereas cumulative incidence of death was not different between the two treatment groups (P= 0.33).</s></p><p><s>In an additional sensitivity analysis we censored patients with death from recurrent primary malignancy at the date of death for EFS.</s><s>The estimated 2-year modified-EFS rate in this analysis was significantly higher in patients treated with ATO-based therapy, including ATO/ ATRA and CTX/ATO/ATRA (95%, 95% CI, 82-99%) as compared to those patients treated with CTX/ATRA (78%, 95% CI, 64-87%; P= 0.042, Figure <ref type="figure" target="#fig_2">2</ref>).</s></p><p><s>In multivariable analysis, neither prior therapy with CTX, nor prior radiation, nor length of latency period from prior malignancy were associated with EFS (P= 0.88, P= 0.34, P= 0.92, respectively), RFS (P= 0.85, P= 0.35, P= 0.88, respectively) or OS (P= 0.77, P= 0.69, P= 0.88, respectively).</s><s>Furthermore, we were interested in the outcome of t-APL patients according to risk categorization (high vs low WBC).</s><s>In univariable analyses, neither EFS (P= 0.57), RFS (P= 0.63), nor OS (P= 0.79) according to initial WBC were different.</s></p><p><s>Three patients relapsed after 9, 12 and 18 months, all after CTX/ATRA treatment.</s><s>In one of these patients, relapse was detected at the MRD level before frank hematological relapse, leading to administration of pre-emptive salvage therapy.</s><s>All of the relapsed APL patients were successfully salvaged with ATO/ATRA ± CTX and went on to autologous (n = 1) or allogeneic transplant (n = 2).</s><s>Two patients developed therapy-related acute myeloid leukemia (t-AML) with a complex karyotype after 47 and 74 months.</s><s>Again, both t-AMLs occurred after CTX/ATRA treatment.</s><s>Both patients were refractory to salvage CTX and died shortly thereafter.</s></p><p><s>Thirteen patients died in APL remission due to relapse of the prior malignancy (CTX/ ATRA, n = 2; ATO/ATRA, n = 1; CTX/ATO/ATRA, n = 1; ATRA, n = 3), infections (CTX/ ATRA, n = 2 and ATO/ATRA, n = 1), development of diffuse large B-cell lymphoma (CTX/ ATRA, n = 1), cardiopulmonary arrest during treatment (ATO/ATRA, n = 1) and unknown reason (CTX/ATRA, n = 1).</s></p><p><s>Regarding toxicity during induction therapy patients who received CTX/ATRA or CTX/ATO/ATRA were categorized into one group, since ATO within the latter treatment scheme was given during consolidation therapy only. <ref type="bibr" target="#b33">34</ref></s><s>Febrile neutropenia of grade ≥ 3 during induction therapy was less frequent in patients treated with ATO/ATRA as compared to CTX/ATRA or CTX/ATO/ATRA (P= 0.03, Table <ref type="table" target="#tab_4">5</ref>), whereas the occurrence of other grade ≥ 3 toxicities was not different between treatment groups.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>Therapy-related APL is increasing in prevalence with longer life expectancy and improved survival of patients treated with chemotherapy and/or radiation for prior malignancies and other disorders. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b38">39</ref></s><s>However, there is a paucity of prospective treatment data since these patients have often been excluded from clinical trials.</s><s>In our retrospective analysis of a large cohort of 103 t-APL patients, spanning a time-period of almost 25 years, more than two thirds of the patients were diagnosed after 2006.</s><s>The median latency period between diagnosis of primary malignancy and occurrence of t-APL was 3.5 years, which is in line with published data. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b38">39</ref></s><s>Consistent with data obtained in t-AML, 8 t-APL patients in our series were older at diagnosis compared to what has been reported in de novo APL, <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b38">39</ref> possibly reflecting the longer life span required to develop two or more malignancies, as well as a prolonged risk exposure.</s><s>In addition, we found a high proportion of female patients (68% were female; P &lt; 0.001), <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b6">7</ref> which may be related to the widespread use of anthracycline-based chemotherapy for breast cancers.</s><s>As previously published for t-AML, 8 younger age at diagnosis of primary malignancy was associated with a shorter latency period to the occurrence of t-APL.</s><s>However, there was no association between treatment with anthracyclines or topo-II inhibitors and a short latency period for the development of t-APL.</s><s>T-APL occurred after treatment of multiple sclerosis with mitoxantrone therapy in only a small number of our patients, but all of them were female, again explaining the higher frequency of female gender in t-APL, as compared to what has been reported in de novo AML.</s><s>In contrast to Beaumont et al., <ref type="bibr" target="#b1">2</ref> who reported a high frequency of 18% of lymphomas prior to the occurrence of t-APL, we did not observe this phenomenon.</s><s>Our series included five patients who had two primary malignancies prior to the diagnosis of t-APL.</s><s>Three of them were treated with CTX/ATRA, one with ATO/ATRA and one with ATRA only.</s><s>The latter one died due to the underlying primary malignancy after 10 months and one patient treated with CTX/ATRA developed a diffuse large B-cell lymphoma after 16 years.</s><s>The other patients were still alive after follow-up times of 7 months, 3.5 years and 9.8 years.</s></p><p><s>Previous studies in t-APL patients reported an incidence of additional abnormalities ranging from 25 to 36%, 2,39 with an even higher incidence of 45% published recently in a singleinstitution report. <ref type="bibr" target="#b39">40</ref></s><s>Although we could not confirm this high incidence of additional abnormalities, the incidence of 26% observed in our cohort is in line with previously published data. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b38">39</ref></s><s>Besides variant translocations and deletions, the most frequently recurring mutation was trisomy 8, again in agreement with published studies. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b39">40</ref></s><s>Concurrent FLT3-ITD mutations were present in 39% and were significantly associated with high WBC at diagnosis, <ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref> which has also been described in de novo APL. <ref type="bibr" target="#b43">44</ref></s><s><ref type="bibr" target="#b46">[47]</ref> Regarding the BCR isoform, we did not observe a higher frequency of the BCR1 isoform in our t-APL patients, and virtually none of our BCR1-positive patients had received prior treatment with topo-II inhibitors, which is in contrast to the data reported by Ottone et al. <ref type="bibr" target="#b50">51</ref> One explanation for the observed discrepancies might be related to substantial differences in the patients analysed.</s><s>Our study included only a low number of patients with t-APL arising after multiple sclerosis, whereas the majority of the t-APL patients published by Ottone et al. <ref type="bibr" target="#b50">51</ref> had multiple sclerosis as their underlying disease, implicating heterogeneous treatments and therefore induction of potentially distinct pathogenetic pathways.</s><s>Nevertheless, both the predominance of the short BCR3 isoform in t-APL <ref type="bibr" target="#b4">5</ref> and the comparable frequency of FLT3-ITD mutations in our cohort to what has been described for de novo APL are in concordance with findings reported by others. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b51">52</ref></s><s>Although there might be a higher susceptibility towards leukemogenesis in t-APL patients, these results suggest a similar composition of de novo as compared to t-APL. <ref type="bibr" target="#b50">51,</ref><ref type="bibr" target="#b52">53</ref></s><s> contrast to published data in de novo APL, high WBC had no impact on outcome. <ref type="bibr" target="#b43">44</ref></s><s>evertheless, our series included only a low number of high-risk patients; thus, no firm conclusion can be drawn regarding this issue.</s></p><p><s>Most of the available studies reported outcome after chemotherapy and ATRA for t-APL patients, <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b38">39</ref> whereas data on outcome after ATO/ATRA are scarce. <ref type="bibr" target="#b39">40</ref></s><s>In our large cohort of 103 t-APL patients, those who had been treated with ATO-based therapy had a higher CR rate and a lower ED rate as compared to patients treated with CTX/ATRA.</s><s>The higher induction mortality in patients treated with CTX/ATRA may reflect the cumulative effect of prior chemotherapies and additional t-APL chemotherapy toxicities.</s><s>General supportive care seemed not to have a major impact on outcome in the years covered in our report, since the ED rate was almost stable over different time-periods.</s><s>However, due to low numbers of events, we could not include the year of treatment in multivariable analysis.</s></p><p><s>If death due to recurrence of the primary malignancy was included as an event, EFS, RFS and OS were not significantly different between patients treated with ATO-based therapy as compared to CTX/ATRA.</s><s>However, if these events were censored at the time point of death, EFS in ATO-based therapy was significantly higher as compared to CTX/ATRA and rates of EFS were very similar to what was achieved in de novo APL. <ref type="bibr" target="#b22">23</ref></s><s>This indicates a similar responsiveness to therapy of t-APL as compared to de novo APL, there by suggesting similar pathogenesis.</s></p><p><s>With a median follow-up of 3.7 years, none of the patients treated with ATO-based therapy have relapsed so far, whereas three patients treated with CTX/ATRA relapsed and two patients developed t-AML with a complex karyotype.</s><s>Again, both t-AMLs occurred after CTX/ATRA treatment.</s><s>Of note, all of the t-APL relapses could be successfully salvaged with ATO/ATRA ± CTX and went on to autologous (n = 1) or allogeneic (n = 2) transplant.</s><s>The absence of secondary therapy-related myeloid neoplasms in patients treated with ATObased regimens represents a potential major improvement in the treatment of a disease in which high cure rates are achieved.</s><s>After a median RFS of 0.7 years (range, 0-16 years), 13 patients experienced other late adverse events, most frequently recurrence of the underlying primary malignancy or infections, whereas t-APL was still in remission.</s></p><p><s>Regarding toxicities during induction therapy, severe febrile neutropenia was significantly less frequent after ATO/ATRA as compared to CTX/ATRA or CTX/ATO/ATRA treatment, again indicating a beneficial effect of the CTX-free approach.</s><s>Nevertheless, due to the retrospective nature and since adverse events had not been documented in all patients, no firm conclusions can be drawn regarding this issue.</s></p><p><s>Since the CTX-free regimen with ATO/ATRA has been proven to be highly effective in de novo APL and has become standard first-line therapy in non-high-risk de novo APL, it seems to be prudent to expand this approach to t-APL. <ref type="bibr" target="#b53">54,</ref><ref type="bibr" target="#b54">55</ref></s><s> EFS according to treatment in intensively treated patients (excluding therapy with ATRA only) with t-APL.</s><s>Death due to the primary malignancy (n = 4) has been censored at the time point of death.</s><s>Abbreviation: t-APL, therapy-related acute promyelocytic leukemia.</s></p><p><s>a Five patients had two solid tumors prior to the occurrence of t-APL (breast and uterus, n = 1; cervix and breast, n = 1; breast and lung, n= 1;</s></p><p><s>ovarian and breast, n = 1; colon/rectum and prostate, n = 1).</s><s>Therefore, the total number of malignancies/non-malignant disorders does not add up to 103.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 2</head><p><s>Therapy of primary malignancy/non-malignant disorder prior to the occurrence of t-APL  Comparison of presenting clinical and laboratory findings according to the applied therapy of patients with t-APL</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>8</head><label>8</label><figDesc><div><p></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Kaplan-Meier plots on EFS (a) and OS (b) in intensively treated patients with t-APL.</s></p></div></figDesc><graphic coords="15,249.24,62.00,173.52,300.54" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2.</s></p></div></figDesc><graphic coords="16,167.28,62.00,337.44,299.52" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><label></label><figDesc><div><p><s>Abbreviations: abn, abnormality; ATO, arsenic trioxide; ATRA, all-trans retinoic acid; BM, bone marrow; CTX, chemotherapy; FAB, French-American-British; ITD, internal tandem duplication; LDH, serum lactate dehydrogenase; No, number; PB, peripheral blood; t-APL, therapy-related acute promyelocytic leukemia; WBC, white blood counts.</s><s>a Risk categorization based on WBC at diagnosis (low/intermediate-risk: WBC &lt; 10.0 G/l; high-risk: WBC ≥ 10.0 G/l).</s><s>Percentages may not add to 100 because of rounding.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Primary diseases in patients with t-APL</s></p></div></figDesc><table><row><cell>Primary diseases</cell><cell>Numbers of patients</cell><cell>%</cell></row><row><cell>Solid cancers</cell><cell>87</cell><cell>84</cell></row><row><cell>Cancers of females</cell><cell></cell><cell></cell></row><row><cell>Breast a</cell><cell>35</cell><cell>34.0</cell></row><row><cell>Cervix a</cell><cell>4</cell><cell>3.9</cell></row><row><cell>Uterus a</cell><cell>6</cell><cell>5.8</cell></row><row><cell>Ovary a</cell><cell>2</cell><cell>1.9</cell></row><row><cell>Cancers of males</cell><cell></cell><cell></cell></row><row><cell>Prostate a</cell><cell>14</cell><cell>13.6</cell></row><row><cell>Testis</cell><cell>2</cell><cell>1.9</cell></row><row><cell>Cerebral cancers</cell><cell></cell><cell></cell></row><row><cell>Pituitary adenoma</cell><cell>1</cell><cell>1.0</cell></row><row><cell>Head and neck cancers</cell><cell></cell><cell></cell></row><row><cell>Thyroid</cell><cell>5</cell><cell>4.9</cell></row><row><cell>Larynx</cell><cell>1</cell><cell>1.0</cell></row><row><cell>Hypopharynx</cell><cell>1</cell><cell>1.0</cell></row><row><cell>Parotic</cell><cell>1</cell><cell>1.0</cell></row><row><cell>Brachial cleft</cell><cell>1</cell><cell>1.0</cell></row><row><cell>Thoracic cancers</cell><cell></cell><cell></cell></row><row><cell>Lung a</cell><cell>3</cell><cell>2.9</cell></row><row><cell>Abdominal cancers</cell><cell></cell><cell></cell></row><row><cell>Esophagus</cell><cell>1</cell><cell>1.0</cell></row><row><cell>Pancreatic</cell><cell>1</cell><cell>1.0</cell></row><row><cell>Colon/rectum a</cell><cell>7</cell><cell>6.8</cell></row><row><cell>Soft tissue tumors</cell><cell></cell><cell></cell></row><row><cell>Liposarcoma</cell><cell>2</cell><cell>1.9</cell></row><row><cell>Hematologic malignancies</cell><cell>8</cell><cell>7.8</cell></row><row><cell>Non-Hodgkin lymphoma</cell><cell>5</cell><cell>4.9</cell></row><row><cell>Hodgkin lymphoma</cell><cell>3</cell><cell>2.9</cell></row><row><cell>Autoimmune diseases</cell><cell>8</cell><cell>7.8</cell></row><row><cell>Multiple sclerosis</cell><cell>4</cell><cell>3.9</cell></row><row><cell>Rheumatologic</cell><cell>4</cell><cell>3.9</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc><div><p><s>Response to induction therapy according to treatment strategy Abbreviations: ATO, arsenic trioxide; ATRA, all-trans retinoic acid; CR, complete remission; CTX, chemotherapy; ED, early death; No, numbers; PR, partial remission.</s></p></div></figDesc><table><row><cell>CR 78 (40)</cell><cell>100 (23)</cell><cell>95 (18)</cell><cell>57</cell></row><row><cell>PR 10 (5)</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>ED 12 (6)</cell><cell>-</cell><cell>5 (1)</cell><cell>43 (3)</cell></row></table><note><p><s>CTX/ATRA % (No.) ATO/ATRA % (No.) CTX/ATO/ATRA % (No.) ATRA only % (No.)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 5</head><label>5</label><figDesc><div><p><s>Grade 3 and higher toxicities according to treatment strategy during induction therapy ATO, arsenic trioxide; ATRA, all-trans retinoic acid; CTX, chemotherapy; No, numbers.Denominators are not consistent with the total number of patients of the respective treatment group due to missing values.a</s><s>Patients who received CTX/ATRA or CTX/ATO/ATRA were categorized into one group since ATO in the latter group was given during consolidation therapy only.</s><s>34 b Anemia and/or thrombopenia and/or neutropenia.</s><s>c Other adverse events: adverse events excluding anemia, thrombopenia or neutropenia.</s><s>Toxicities were classified according to CTCAE v. 4.0.</s></p></div></figDesc><table><row><cell>Febrile neutropenia</cell><cell>23/34 (68)</cell><cell>3/11 (27)</cell><cell>0.03</cell></row><row><cell>Hematological adverse events b</cell><cell>32/34 (94)</cell><cell>9/11 (82)</cell><cell>0.25</cell></row><row><cell>c Other adverse events</cell><cell>30/41 (73)</cell><cell>11/15 (73)</cell><cell>1.00</cell></row><row><cell>Abbreviations:</cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>CTX/ATRA &amp; CTX/ATO/ATRA a no.</s><s>(%) ATO/ATRA no.</s><s>(%) P-value Leukemia.</s><s>Author manuscript; available in PMC 2018 July 09.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Leukemia. Author manuscript; available in PMC 2018 July 09.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>SK gratefully acknowledges to be supported by the Olympia-Morata fellowship program from the Medical Faculty of the Heidelberg University.</s><s>MJL is supported by a grant from the NCI (NCI Leukemia SPORE P50 CA100632).</s><s>RBW is a Leukemia &amp; Lymphoma Society Scholar in Clinical Research.</s><s>ZR, JM, JN, PZ and TS were supported by the Ministry of the Czech Republic, grant No. 15-25809A.</s><s>UP was supported by a grant from the Deutsche Forschungsgemeinschaft (DFG SFB-655).</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Biology and management of therapy-related acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">F</forename><surname>Lo-Coco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Hasan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Montesinos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Sanz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="695" to="700" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 24076582</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Therapy-related acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Beaumont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Carli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Maloisel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Detourmignies</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="2123" to="2137" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12775738</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Secondary acute promyelocytic leukemia: an increasingly common entity</title>
		<author>
			<persName><forename type="first">E</forename><surname>Jantunen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Heinonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mahlamäki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Penttilä</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kuittinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lehtonen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="190" to="191" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17325866</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">DNA topoisomerase II in therapy-related acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Mistry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Felix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Whitmarsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Reiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Cassinat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">352</biblScope>
			<biblScope unit="page" from="1529" to="1538" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 15829534</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group</title>
		<author>
			<persName><forename type="first">T</forename><surname>Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cereja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chevret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Raffoux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Beaumont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Detourmignies</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="2393" to="2399" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25845577</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Elliott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Letendre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tefferi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Hogan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Kaufmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Haematol</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="237" to="243" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 22023492</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience</title>
		<author>
			<persName><forename type="first">A</forename><surname>Pulsoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pagano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lo-Coco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Avvisati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Bona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="1972" to="1976" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 12200354</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kayser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Döhner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Krauter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Köhne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Horst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Held</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="2137" to="2145" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 21127174</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Therapy-related AML: a slip of the lip can sink a ship</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Gale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">O</forename><surname>Hoffman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Res</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="418" to="420" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 24439054</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Doss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Khanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Thompson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="100" to="111" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>PubMed: 27923552</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Clonal haemopoiesis and therapyrelated myeloid malignancies in elderly patients: a proof-of-concept, case-control study</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Gillis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ball</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Yoder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="112" to="121" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>PubMed: 27927582</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Analysis of t (15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Hasan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ottone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Schlenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Wiemels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Mitra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genes Chromosomes Cancer</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="726" to="732" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20544846</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t (15;17) therapyrelated acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Mays</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Osheroff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Wiemels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Felix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Byl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="326" to="330" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 19884644</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Chai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">X</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhoa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="567" to="572" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
	<note>PubMed: 3165295</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Revisiting the differentiation paradigm in acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ablain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>De The</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="5795" to="5802" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 21444912</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results</title>
		<author>
			<persName><forename type="first">S</forename><surname>Castaigne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chomienne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ballerini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fenaux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="1704" to="1709" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
	<note>PubMed: 2224119</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Q</forename><surname>Xue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">M</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="1413" to="1419" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note>PubMed: 1884013</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship</title>
		<author>
			<persName><forename type="first">C</forename><surname>Chomienne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ballerini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Balitrand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fenaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Castaigne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="1710" to="1717" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
	<note>PubMed: 2224120</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid</title>
		<author>
			<persName><forename type="first">L</forename><surname>Degos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chomienne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dombret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fenaux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">336</biblScope>
			<biblScope unit="page" from="1440" to="1441" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Warrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Frankel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Scheinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Itri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">N</forename><surname>Hittelman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">324</biblScope>
			<biblScope unit="page" from="1385" to="1393" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note>PubMed: 1850498</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Acute promyelocytic leukemia: where did we start, where are we now, and the future</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Coombs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tavakkoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Tallman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood Cancer J</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">e304</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25885425</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">E</forename><surname>Estey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Garcia-Manero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ferrajoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Faderl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Verstovsek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jones</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="3469" to="3473" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>PubMed: 16373661</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Retinoic acid and arsenic trioxide for acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">F</forename><surname>Lo-Coco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Avvisati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vignetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thiede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Orlando</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Iacobelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="111" to="121" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23841729</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Arsenic trioxide and alltrans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Burnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Hills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bowen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Knapper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1295" to="1305" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 26384238</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Catovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Flandrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Galton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Gralnick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="620" to="625" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
	<note>PubMed: 3862359</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Cheson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Kopecky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Büchner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Willman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Estey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="4642" to="4649" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 14673054</note>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title level="m" type="main">ISCN: An International System for Human Cytogenetic NomenclatureS Karger</title>
		<author>
			<persName><forename type="first">F</forename><surname>Mitelman</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines</title>
		<author>
			<persName><forename type="first">S</forename><surname>Yokota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kiyoi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nakao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Iwai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Misawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Okuda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1605" to="1609" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9324277</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Thiede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Steudel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mohr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schaich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schäkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Platzbecker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="4326" to="4335" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 12036858</note>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title level="m" type="main">Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell&apos;Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups Blood</title>
		<author>
			<persName><forename type="first">F</forename><surname>Mandelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Diverio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Avvisati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Luciano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Barbui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bernasconi</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1997">1997</date>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="1014" to="1021" />
		</imprint>
	</monogr>
	<note>PubMed: 9242531</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Sanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Martín</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>González</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>León</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rayón</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rivas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="1237" to="1243" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 14576047</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Sanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Montesinos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rayón</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Holowiecka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>De La Serna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Milone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="5137" to="5146" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20393132</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Burnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Hills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Grimwade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Jovanovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Craig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Mcmullin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="843" to="851" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23222369</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Gore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Gojo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Sekeres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Devetten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jamieson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1047" to="1053" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20085935</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">A note on quantifying follow-up in studies of failure time</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schemper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Control Clin Trials</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="343" to="346" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8889347</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Nonparametric estimation from incomplete observations</title>
		<author>
			<persName><forename type="first">E</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Meier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Stat Assoc</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="457" to="481" />
			<date type="published" when="1958">1958</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Regression models and life tables (with discussion)</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Cox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J RSt at Soc</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="187" to="220" />
			<date type="published" when="1972">1972</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title level="m" type="main">TeamR: A language and environment for statistical computingR Foundation for Statistical Computing</title>
		<author>
			<persName><surname>Development Core</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page">2014</biblScope>
			<pubPlace>Vienna, Austria</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Clinical and pathologic features of secondary acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Duffield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Aoki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Levis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Cowan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Gocke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Burns</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="395" to="402" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 22338051</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy</title>
		<author>
			<persName><forename type="first">F</forename><surname>Dayyani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>O'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pierce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Faderl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="110" to="115" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 20803607</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho)</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kiyoi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Naoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yokota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nakao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Minami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kuriyama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1447" to="1452" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9305596</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">I</forename><surname>Noguera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Breccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Divona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Diverio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Santis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="2185" to="2189" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 12399960</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Y</forename><surname>Shih</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Kuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="1206" to="1216" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12973844</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Highdose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Schlenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Germing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Glasmacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Del Valley Fuentes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="978" to="983" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 15843821</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>De Botton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chevret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dombret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Guerci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="801" to="806" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 11122141</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Lou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Suo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Res</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1451" to="1456" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23958062</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy</title>
		<author>
			<persName><forename type="first">J</forename><surname>Cervera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Montesinos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hernández-Rivas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Calasanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Aventín</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Ferro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="424" to="431" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 19903674</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence</title>
		<author>
			<persName><forename type="first">M</forename><surname>Pantic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Novak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Marisavljevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Djordjevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Elezovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vidovic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="307" to="313" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 11114710</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype</title>
		<author>
			<persName><forename type="first">X</forename><surname>Poiré</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Moser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Gallagher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Laumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Bloomfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Powell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1523" to="1532" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 24160850</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy</title>
		<author>
			<persName><forename type="first">L</forename><surname>Cicconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Divona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ciardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ottone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ferrantini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lavorgna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1987" to="1992" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 27133819</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ottone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cicconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Hasan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lavorgna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Divona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Voso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Res</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="474" to="478" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 22071137</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Glassman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Valbuena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Luthra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="840" to="848" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 15899774</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia</title>
		<author>
			<persName><forename type="first">V</forename><surname>Madan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Shyamsunder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mayakonda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nagata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sundaresan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1672" to="1681" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 27063598</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-highrisk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial</title>
		<author>
			<persName><forename type="first">U</forename><surname>Platzbecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Avvisati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cicconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thiede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Paoloni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vignetti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="605" to="612" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 27400939</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Abaza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Garcia-Manero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Estey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Borthakur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Jabbour</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="1275" to="1283" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 28003274</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
